RxDoctor Payments Data

James Cimbak

Corneal and Contact Management · Horsham, PANPI 1134270515

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Johnson & Johnson Vision Care, Inc. at 41.8% of the total. 2025 is the largest year on record at $609, 5.1 times the $118 reported in 2019.

$1,558in general payments, 2019–2025

Across 63 payments — averaging $24.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$651
  • Alcon$233
  • Tarsus Pharmaceuticals, Inc.$178
  • Bausch & Lomb Americas Inc.$175
  • Optovue, Inc.$118
  • Oyster Point Pharma, Inc.$75
  • plus $128 from 4 others

What the payments were for

  • Food & beverage$1,558100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,558 in reported general payments places this provider in the 80th percentile of 43 corneal and contact management providers in Pennsylvania.

See all corneal and contact management providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$36,430
Medicare patients
262
Services billed
411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tobramycin-DexamethasoneTobramycin/Dexamethasone33$1,210
Fluorometholone15$681
Ofloxacin15$251
ErythromycinErythromycin Base13$164

Paid to pharmacies, not to this prescriber.

Other corneal and contact management in Horsham

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →